What is HC Wainwright’s Estimate for CRDF Q3 Earnings?

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Research analysts at HC Wainwright issued their Q3 2026 EPS estimates for shares of Cardiff Oncology in a report released on Tuesday, September 15th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($0.13) per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Cardiff Oncology’s Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.56) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.33) EPS.

Cardiff Oncology (NASDAQ:CRDF) last released its earnings results on Tuesday, August 11th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The business had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.06 million. Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%.

A number of other equities research analysts also recently commented on CRDF. Craig Hallum downgraded Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a research report on Wednesday, June 3rd. Weiss Ratings raised Cardiff Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, September 4th. William Blair downgraded Cardiff Oncology from an “outperform” rating to a “market perform” rating in a report on Tuesday, August 11th. Wall Street Zen raised Cardiff Oncology from a “strong sell” rating to a “sell” rating in a report on Saturday, September 5th. Finally, TD Cowen lowered Cardiff Oncology from a “buy” rating to a “hold” rating in a research report on Monday, June 1st. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $7.50.

Cardiff Oncology Stock Performance

Cardiff Oncology stock opened at $1.35 on Thursday. The firm has a market cap of $105.02 million, a price-to-earnings ratio of -2.25 and a beta of 1.46. Cardiff Oncology has a 1 year low of $0.76 and a 1 year high of $3.31. The firm’s 50 day moving average price is $1.01 and its two-hundred day moving average price is $1.41.

Institutional Trading of Cardiff Oncology

Large investors have recently added to or reduced their stakes in the company. Engineers Gate Manager LP purchased a new stake in shares of Cardiff Oncology in the second quarter valued at $32,000. Squarepoint Ops LLC grew its holdings in shares of Cardiff Oncology by 264.6% during the second quarter. Squarepoint Ops LLC now owns 96,090 shares of the company’s stock valued at $125,000 after buying an additional 69,734 shares in the last quarter. Hsbc Holdings PLC acquired a new position in Cardiff Oncology during the second quarter valued at $37,000. Glenview Trust Co acquired a new position in Cardiff Oncology during the second quarter valued at $56,000. Finally, Capstone Investment Advisors LLC purchased a new stake in Cardiff Oncology in the 2nd quarter worth about $67,000. 16.29% of the stock is owned by institutional investors and hedge funds.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead investigational product is onvansertib, an oral, highly selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cell division and cancer-cell growth.

Cardiff Oncology has primarily studied onvansertib in combination with existing treatments for patients with difficult-to-treat solid tumors, including KRAS-mutated metastatic colorectal cancer.